CHEM-MASTER INTERNATIONAL, INC

CHEM-MASTER INTERNATIONAL, INC specializes in the synthesis and formulation of proprietary organic chemical compounds for pharmaceutical applications, with demonstrated expertise in developing active pharmaceutical ingredients for inflammatory disease therapeutics. The company’s technical capabilities center on advanced organic synthesis, purification methodologies, and process scale-up for bioactive molecules, leveraging precision chemistry to produce high-purity intermediates and final drug compounds. Their work aligns with Good Manufacturing Practice (GMP) standards required for clinical-stage drug development, indicating a focus on controlled, reproducible chemical processes suitable for regulatory submission. Differentiators include targeted molecular design for biological activity and experience in translating laboratory-scale chemistry into viable manufacturing workflows for government-funded biomedical programs. The contractor has delivered chemical manufacturing services to the Department of Health and Human Services, specifically supporting drug development initiatives for inflammatory conditions. This suggests a consistent engagement with HHS components such as the National Institutes of Health or the Biomedical Advanced Research and Development Authority, where specialized chemical synthesis is critical to advancing novel therapeutics. The relationship reflects a niche role as a contract manufacturer for mission-critical pharmaceutical intermediates under federal research and development programs. The primary NAICS code 325199 reflects activity in the production of other basic organic chemicals not elsewhere classified, which in practice means the company operates in the specialized segment of fine chemical manufacturing for pharmaceutical use rather than bulk commodity production. This positions them as a technical supplier to the biopharmaceutical sector, serving government-funded drug discovery and development pipelines. CHEM-MASTER INTERNATIONAL, INC is structured as a small business (2L) with its operational base in Hauppauge, New York. While no federal certifications are listed, their ability to deliver compounds for HHS-funded drug programs indicates adherence to stringent quality and regulatory protocols essential for federal biomedical contracts. The company’s geographic presence supports access to Northeastern biotech and academic research ecosystems.